Rhinitis Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharma, Inmunotek SL

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Rhinitis pipeline constitutes 35+ key companies continuously working towards developing 35+ Rhinitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Rhinitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Rhinitis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rhinitis Market.

Some of the key takeaways from the Rhinitis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Rhinitis treatment therapies with a considerable amount of success over the years.

*
Rhinitis companies working in the treatment market are Funpep, Inimmune, Chia Tai Tianqing Pharmaceutical Group, Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inmunotek SL, Abdi Ibrahim Pharmaceuticals, Regeneron, Revelation Biosciences, Qyuns Therapeutics, Hyloris Pharmaceuticals, and others, are developing therapies for the Rhinitis treatment

*
Emerging Rhinitis therapies in the different phases of clinical trials are- FPP004, INI 2004, TQC 3564, ILT-101, IRL201104, PA9159, MM09-MG01, AI201901, REGN1908-1909, Glycopyranosyl lipid adjuvant, QX 005N, HY-083, and others are expected to have a significant impact on the Rhinitis market in the coming years.

*
In June 2023, Longbio Pharma (Suzhou) has announced encouraging top-line findings from a Phase I clinical trial of LP-003, a novel long-acting anti-IgE antibody designed for allergic rhinitis treatment. This double-blind, randomized study assessed the pharmacokinetics, pharmacodynamics (free IgE levels), and safety of LP-003 in healthy participants.

*
In May 2023, Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company committed to addressing critical unmet medical needs, has disclosed favorable and statistically significant top-line outcomes from the randomized controlled NASAR clinical trial assessing its Bentrio nasal spray in individuals with seasonal allergic rhinitis (SAR). Bentrio nasal spray is crafted as a drug-free and preservative-free gel emulsion aimed at providing protection against airborne allergens like pollen or house dust mites.

Rhinitis Overview

Rhinitis is a medical term used to describe inflammation of the mucous membrane lining the nose. It is a common condition that typically presents with symptoms such as a runny or congested nose, sneezing, itching, and nasal discharge. Rhinitis can be classified into several types, including allergic rhinitis, non-allergic rhinitis, and infectious rhinitis.

Get a Free Sample PDF Report to know more about Rhinitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/rhinitis-pipeline [https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Rhinitis Drugs Under Different Phases of Clinical Development Include:

*
FPP004: Funpep

*
INI 2004: Inimmune

*
TQC 3564: Chia Tai Tianqing Pharmaceutical Group

*
ILT-101: Iltoo Pharma

*
IRL201104: Revolo Biotherapeutics

*
PA9159: Anhui Palo Alto Pharmaceuticals

*
MM09-MG01: Inmunotek SL

*
AI201901: Abdi Ibrahim Pharmaceuticals

*
REGN1908-1909: Regeneron

*
Glycopyranosyl lipid adjuvant: Revelation Biosciences

*
QX 005N: Qyuns Therapeutics

*
HY-083: Hyloris Pharmaceuticals

Rhinitis Route of Administration

Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Rhinitis Molecule Type

Rhinitis Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Rhinitis Pipeline Therapeutics Assessment

*
Rhinitis Assessment by Product Type

*
Rhinitis By Stage and Product Type

*
Rhinitis Assessment by Route of Administration

*
Rhinitis By Stage and Route of Administration

*
Rhinitis Assessment by Molecule Type

*
Rhinitis by Stage and Molecule Type

DelveInsight's Rhinitis Report covers around 35+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Rhinitis product details are provided in the report. Download the Rhinitis pipeline report to learn more about the emerging Rhinitis therapies [https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Rhinitis Therapeutics Market include:

Key companies developing therapies for Rhinitis are - Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others.

Rhinitis Pipeline Analysis:

The Rhinitis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Rhinitis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rhinitis Treatment.

*
Rhinitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Rhinitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rhinitis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Rhinitis drugs and therapies [https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Rhinitis Pipeline Market Drivers

*
Increase in the prevalence of various form of rhinitis, surge in the demand for effective and potent drugs among consumers across the globe are some of the important factors that are fueling the Rhinitis Market.

Rhinitis Pipeline Market Barriers

*
However, high competition from generic drugs, side-effects associated with the rhinitis treatment and other factors are creating obstacles in the Rhinitis Market growth.

Scope of Rhinitis Pipeline Drug Insight

*
Coverage: Global

*
Key Rhinitis Companies: Funpep, Inimmune, Chia Tai Tianqing Pharmaceutical Group, Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inmunotek SL, Abdi Ibrahim Pharmaceuticals, Regeneron, Revelation Biosciences, Qyuns Therapeutics, Hyloris Pharmaceuticals, and others

*
Key Rhinitis Therapies: FPP004, INI 2004, TQC 3564, ILT-101, IRL201104, PA9159, MM09-MG01, AI201901, REGN1908-1909, Glycopyranosyl lipid adjuvant, QX 005N, HY-083, and others

*
Rhinitis Therapeutic Assessment: Rhinitis current marketed and Rhinitis emerging therapies

*
Rhinitis Market Dynamics: Rhinitis market drivers and Rhinitis market barriers

Request for Sample PDF Report for Rhinitis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Rhinitis Report Introduction

2. Rhinitis Executive Summary

3. Rhinitis Overview

4. Rhinitis- Analytical Perspective In-depth Commercial Assessment

5. Rhinitis Pipeline Therapeutics

6. Rhinitis Late Stage Products (Phase II/III)

7. Rhinitis Mid Stage Products (Phase II)

8. Rhinitis Early Stage Products (Phase I)

9. Rhinitis Preclinical Stage Products

10. Rhinitis Therapeutics Assessment

11. Rhinitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Rhinitis Key Companies

14. Rhinitis Key Products

15. Rhinitis Unmet Needs

16 . Rhinitis Market Drivers and Barriers

17. Rhinitis Future Perspectives and Conclusion

18. Rhinitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=rhinitis-pipeline-and-clinical-trials-assessment-2024-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-iltoo-pharma-revolo-biotherapeutics-anhui-palo-alto-pharma-inmunotek-sl]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.